Workflow
美疾控疫苗团队改组引持续争议
Jing Ji Guan Cha Wang·2025-06-18 11:00

Core Viewpoint - The restructuring of the CDC's Advisory Committee on Immunization Practices (ACIP) has sparked significant controversy, with former members warning that it could severely undermine the U.S. vaccination program and access to life-saving vaccines [1][2]. Group 1: Impact on Vaccine Companies - Following the dismissal of the 17 ACIP members, shares of several vaccine companies have declined: Moderna (MRNA) down 9.2%, Novavax (NVAX) down 12.4%, Merck (MRK) down 1.4%, and Pfizer (PFE) slightly up by 0.1% [1]. - The decisions made by ACIP directly influence vaccination programs for children, insurance reimbursement, and government procurement [1]. Group 2: Controversy Surrounding Dismissal - The dismissal was initiated by Robert F. Kennedy Jr., the new Secretary of Health and Human Services, who claimed that the former committee members had conflicts of interest with vaccine companies [2]. - Former ACIP members refuted these claims, asserting that they adhered to strict conflict-of-interest guidelines and that the committee was one of the most transparent federal bodies [2]. Group 3: Reappointment of New Members - After the dismissal, Kennedy appointed 8 new members to ACIP, some of whom have publicly expressed anti-vaccine views, raising concerns about the committee's future direction [3]. - The restructured ACIP is expected to hold a meeting from June 25 to 27 to vote on vaccine recommendations for COVID-19, HPV, influenza, meningococcal, and RSV [3]. Group 4: Broader Implications of Kennedy's Policies - Kennedy's administration has initiated significant reforms, including a major restructuring of the Department of Health and Human Services, which could lead to budget cuts of 30% to 40% for the NIH and CDC [5]. - His controversial proposals include restricting federally funded scientists from publishing in major medical journals, which has raised concerns about academic freedom [5].